Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

被引：0

作者：

Kumar, Shaji ^{[1
]}

Jagannath, Sundar ^{[2
]}

Weisel, Katja C. ^{[3
]}

Dachs, Laura Rosinol ^{[4
]}

Dimopoulos, Meletios-Athanasios ^{[5
]}

Siegel, David S. ^{[6
]}

Monge, Jorge ^{[7
]}

Leleu, Xavier ^{[8
]}

Du, Juan ^{[9
]}

de la Rubia, Javier ^{[10
]}

Lee, Jae Hoon ^{[11
]}

Mateos, Maria-Victoria ^{[12
]}

Gozzetti, Alessandro ^{[13
]}

Dytfeld, Dominik ^{[14
]}

Ocio, Enrique M. ^{[15
]}

Blade, Joan

Ozaki, Shuji ^{[16
]}

Nagaraj, Madhu ^{[17
]}

Hassan, Rafla ^{[17
]}

Green, Jeannette ^{[18
]}

Kroog, Glenn S. ^{[18
]}

Lorenc, Karen Rodriguez ^{[18
]}

Hampp, Christian ^{[18
]}

Ma, Qiufei ^{[18
]}

Durie, Brian G. M. ^{[19
]}

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Mt Sinai Med Ctr, New York, NY USA

[3] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] Univ Athens, Sch Med, Athens, Greece

[6] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[7] Weill Cornell Med, New York, NY USA

[8] Ctr Hosp Univ, Poitiers, France

[9] Shanghai Changzheng Hosp, Myeloma & Lymphoma Ctr, Dept Hematol, Shanghai, Peoples R China

[10] Hosp Univ La Fe, Valencia, Spain

[11] Gachon Univ, Gil Med Ctr, Incheon, South Korea

[12] Biomed Res Inst Salamanca, Salamanca, Spain

[13] Univ Siena, I-53100 Siena, Italy

[14] Poznan Univ Med Sci, Poznan, Poland

[15] Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain

[16] Tokushima Prefectural Cent Hosp, Tokushima, Japan

[17] Mayo Clin, Div Hematol, Rochester, MN USA

[18] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[19] Cedars Sinai Med Ctr, Los Angeles, CA USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-210376

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7039 / 7041

页数：3

共 50 条

[1] Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis
Kumar, Shaji
Jagannath, Sundar
Weisel, Katja C.
Dachs, Laura Rosinol
Dimopoulos, Meletios-Athanasios
Siegel, David S.
Monge, Jorge
Leleu, Xavier
Du, Juan
de la Rubia, Javier
Lee, Jae Hoon
Mateos, Maria-Victoria
Martinez, Borja Puertas
Gozzetti, Alessandro
Dytfeld, Dominik
Ocio, Enrique M.
Blade, Joan
Ozaki, Shuji
Beksac, Meral
Escalante, Fernando
Nagaraj, Madhu
Hassan, Rafla
Spin, Paul
Bonar, Nicolle
Shokoohi, Mostafa
Siddiqui, Muhaimen
Wang, Di
Hou, Kevin
Green, Jeannette
Humblet, Olivier
Breskin, Alexander
Harnett, James
Ge, Wenzhen
Sobel, Rachel E.
Jalbert, Jessica J.
Kroog, Glenn S.
Lorenc, Karen Rodriguez
Ma, Qiufei
Hampp, Christian
Durie, Brian G. M.
BLOOD, 2024, 144 : 7012 - 7014
[2] Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Kumar, Shaji
Weisel, Katja C.
Ma, Qiufei
Hampp, Christian
Humblet, Olivier
Shokoohi, Mostafa
Bonar, Nicolle
Spin, Paul
Harnett, James
Ge, Wenzhen
Jalbert, Jessica J.
Sobel, Rachel E.
Kroog, Glenn Scott
Rodriguez-Lorenc, Karen
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
Krishnan, Amrita Y.
Nooka, Ajay K.
Chari, Ajai
Garfall, Alfred L.
Martin, Thomas G.
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Pei, Lixia
Eric, Ammann
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok V.
Slavcev, Mary
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Ye, Jing Christine
Biran, Noa
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Ammann, Eric
Renaud, Thomas
Kane, Colleen
Parekh, Trilok
Gray, Kathleen
Peterson, Steve
Costa, Luciano J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (02):
[5] Comparative effectiveness of teclistamab versus real-world physician's choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma
Krishnan, Amrita
Nooka, Ajay
Chari, Ajai
Garfall, Alfred
Martin, Thomas
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok
Marshall, Alexander
Slavcev, Mary
Usmani, Saad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S174 - S174
[6] Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Philippe Moreau
María-Victoria Mateos
Maria Esther Gonzalez Garcia
Hermann Einsele
Valerio De Stefano
Lionel Karlin
Joanne Lindsey-Hill
Britta Besemer
Laure Vincent
Suriya Kirkpatrick
Michel Delforge
Aurore Perrot
Niels W. C. J. van de Donk
Charlotte Pawlyn
Salomon Manier
Xavier Leleu
Joaquin Martinez-Lopez
Francesca Ghilotti
Joris Diels
Raúl Morano
Claire Albrecht
Vadim Strulev
Imène Haddad
Lixia Pei
Rachel Kobos
Jennifer Smit
Mary Slavcev
Alexander Marshall
Katja Weisel
Advances in Therapy, 2024, 41 : 696 - 715
[7] Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Moreau, Philippe
Mateos, Maria-Victoria
Gonzalez Garcia, Maria Esther
Einsele, Hermann
De Stefano, Valerio
Karlin, Lionel
Lindsey-Hill, Joanne
Besemer, Britta
Vincent, Laure
Kirkpatrick, Suriya
Delforge, Michel
Perrot, Aurore
van de Donk, Niels W. C. J.
Pawlyn, Charlotte
Manier, Salomon
Leleu, Xavier
Martinez-Lopez, Joaquin
Ghilotti, Francesca
Diels, Joris
Morano, Raul
Albrecht, Claire
Strulev, Vadim
Haddad, Imene
Pei, Lixia
Kobos, Rachel
Smit, Jennifer
Slavcev, Mary
Marshall, Alexander
Weisel, Katja
ADVANCES IN THERAPY, 2024, 41 (02) : 686 - 695
[8] Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Jagannath, Sundar
Lee, Hans C.
Richter, Joshua Ryan
Zonder, Jeffrey A.
Hoffman, James E.
Zhou, Zheng-Yi
Horton, Viviana Garcia
Fillbrunn, Mirko
Wang, Hongjue
Mattera, Matthew
Ma, Qiufei
Inocencio, Timothy J.
Xu, Yingxin
Bergrath, Evelien
Harnett, James
Roccia, Tito
Kroog, Glenn Scott
Rodriguez-Lorenc, Karen
Houvras, Yariv
Bumma, Naresh
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
Krishnan, Amrita
Nooka, Ajay K.
Chari, Ajai
Garfall, Alfred L.
Martin, Thomas G.
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok
Marshall, Alexander
Slavcev, Mary
Usmani, Saad Z.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (06)
[10] Indirect Comparison of Linvoseltamab Versus Talquetamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Richter, Joshua
Jagannath, Sundar
Lee, Hans
Hoffman, James E.
Zonder, Jeffrey
Zhou, Zheng-Yi
Garcia-Horton, Viviana
Fillbrunn, Mirko
Wang, Hongjue
Mattera, Matthew
Ma, Wenxin
Ma, Qiufei
Inocencio, Timothy
Xu, Yingxin
Bergrath, Evelien
Harnett, James
Roccia, Tito
Kroog, Glenn S.
Lorenc, Karen Rodriguez
Houvras, Yariv
Bumma, Naresh
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S274 - S275

← 1 2 3 4 5 →